Md Sadique Hussain’s Post

▶️ 📝 📈 Visit our poster at Society for Neuroscience's annual conference, Neuroscience 24! 🖱️ Click this ➡️ link to add it to your show: https://buff.ly/4gh1EZj October 9, 2024, 8:00 AM - 12:00 PM 📝 Abstract 📝 Alzheimer's disease (AD) presents a formidable challenge for researchers and drug developers. Traditional preclinical AD mouse models often exhibit protracted disease progression, which makes discovery and drug development time-consuming and costly. To address this challenge, we generated the FAD3T (APP/PS1/Tau) transgenic mouse model, which encompasses three mutations that mirror pivotal genetic factors implicated in AD pathogenesis. #SFN #Neuroscience #AlzheimersDisease #DrugDevelopment

🔬 Biocytogen’s Advanced Neurobehavioral Testing Platform 🔬 Genetic rodent models are crucial for offering insights into the behavior, pathology, and potential CNS therapies for neurobehavioral disorders. At Biocytogen, we provide a comprehensive portfolio of genetically humanized mouse models and advanced CNS disease models, along with a cutting-edge neurobehavioral testing platform to evaluate phenotypes across key functions, including anxiety, cognition, learning, memory, movement, perception, and more. Innovate the future of neurobehavioral research with us!🚀 #NeuroScience #Biocytogen #CNSResearch #NeurobehavioralTesting #Pharmacology #BiotechInnovations #ResearchAdvances #GeneticModels #InnovationInScience

▶️ 📝 📈 𝑳𝒂𝒔𝒕 𝒓𝒆𝒎𝒊𝒏𝒅𝒆𝒓! Visit our poster at Society for Neuroscience's annual conference, Neuroscience 2024! 🖱️ Click this ➡️ link to add it to your show: https://buff.ly/4gh1EZj October 9, 2024, 8:00 AM - 12:00 PM 🤝 Message us to meet at the show! 📝 Abstract 📝 Alzheimer's disease (AD) presents a formidable challenge for researchers and drug developers. Traditional preclinical AD mouse models often exhibit protracted disease progression, which makes discovery and drug development time-consuming and costly. To address this challenge, we generated the FAD3T (APP/PS1/Tau) transgenic mouse model, which encompasses three mutations that mirror pivotal genetic factors implicated in AD pathogenesis. #SFN24 #Neuroscience #AlzheimersDisease #MouseModel #DrugDevelopment

Today is World Parkinson’s Day, an opportunity to raise awareness and understanding about Parkinson’s Disease. Parkinson’s Disease (PD) is a neurological disorder affecting millions of individuals worldwide. Since it does not yet have a cure, researchers are conducting groundbreaking research to unravel the cells at play when this disease presents itself and to discover new #therapeutics. Learn more about World Parkinson’s Day: https://lnkd.in/dFHFy2Rz Our most recent Inscopix, Inc. blog, “Honoring World Parkinson’s Day: Driving neural circuit advances in Parkinson’s therapeutics with Inscopix miniscopes” starts with our current understanding of PD, symptoms, and treatments. It then presents four publications from researchers using Inscopix miniscopes and innovative experimental techniques for new insights into the disease. Read the full blog: https://lnkd.in/dnQxyM98 #worldparkinsonsday #neuroscience #microscopy

🚀 We’re thrilled to announce the launch of NeuroAdapt! This €2M programme, co-funded by the European Commission's MSCA 2023 COFUND and FutureNeuro, will empower 11 postdocs from around the world to engage in pioneering neuroscience research, focusing on areas such as gene therapy and precision medicine—all designed to enhance patient care. What sets NeuroAdapt apart is its commitment to bridging the gap between research and real-world application. By incorporating clinical and industry placements, as well as insights from individuals living with neurological conditions, we ensure that our work is relevant and impactful. Together, we will strengthen Ireland's position as a leader in neuroscience while aligning with critical health priorities.  Discover more about NeuroAdapt here: https://lnkd.in/eyk6DsxD #Neuroscience #Postdoc #ResearchTraining #NeuroAdapt #FutureNeuro #PatientCare  Research Ireland European Commission Tobias Engel Fergal O'Brien Royal College of Surgeons in Ireland (RCSI) Trinity College Dublin University College Dublin Dublin City University University of Galway Maynooth University University College Cork South East Technological University 

We are excited to attend the AD/PD - Advances in Science & Therapy in Lisbon! 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘄𝗮𝘀 𝗱𝗲𝗲𝗺𝗲𝗱 𝗮 𝗱𝗶𝘀𝘁𝗮𝗻𝘁 𝗱𝗿𝗲𝗮𝗺 𝗮 𝗳𝗲𝘄 𝗱𝗲𝗰𝗮𝗱𝗲𝘀 𝗮𝗴𝗼. The development of neurospheroids and brain organoid models has revolutionized research and therapeutics for #Alzheimer's and #Parkinson’s disease. This breakthrough will allow physicians to prescribe tailored drugs previously tested in patient’s 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models. In this video, we record electrical activity from a cortico-hippocampal assembloid. What about testing compounds in #brainorganoids? Come visit our neuroscientists Diego Fernández and Elisa Monz at booth #26 to find out how our 𝗖𝗼𝗿𝗲𝗣𝗹𝗮𝘁𝗲™ -𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗺𝘂𝗹𝘁𝗶𝘄𝗲𝗹𝗹 𝘀𝘆𝘀𝘁𝗲𝗺 can help your research on #neurodegenerative diseases in 3D models, #brainslices, and cell cultures. #electrophysiology #organoidmodel #neuroscience #brainorganoid #neurospheres #retinalorganoid #neurosciencebreakthrough #understandingthebrain #futureofneuroscience #neurosciencecommunity #scientificadvancements #neuroscienceexploration #adpd2024

Molecular Mechanism of Alpha-Synuclein in Parkinson's Disease Alpha-synuclein is central to the pathology of Parkinson's disease. Here’s a breakdown of its molecular mechanism:Misfolding: Normally, alpha-synuclein helps with neurotransmitter release. However, it can misfold and form toxic aggregates. Aggregation: Misfolded alpha-synuclein clumps together, forming Lewy bodies that disrupt cellular functions. Mitochondrial Dysfunction: These aggregates can impair mitochondrial function, leading to energy deficits and increased oxidative stress in neurons. Neuroinflammation: The presence of Lewy bodies triggers an inflammatory response, further damaging surrounding neurons. Neuronal Death: Over time, the cumulative effects lead to the degeneration of dopamine-producing neurons, causing the hallmark symptoms of Parkinson's. Understanding this mechanism is crucial for developing targeted therapies. Stay aware and support Parkinson’s research! Parkinson's Ireland #ParkinsonsDisease #AlphaSynuclein #Neuroscience

🔬 Advancing Parkinson’s Disease Research at PsychoGenics! We're excited to highlight insights from our work with the Line 61 mouse model, a vital tool in our arsenal for understanding Parkinson’s disease. Our research has provided detailed observations on motor deficits, protein aggregation, and neuroinflammation which are key to unraveling the complexities of this disorder. Highlights: 🧬 Line 61 HET mice exhibit pronounced motor impairments and muscle strength deficits, observable from as early as 9 weeks. 📊 Our analysis shows increased levels of both phospho and total α-synuclein in striatal tissues at 15 weeks, indicating significant pathological changes. 🧪 Immunohistochemistry reveals distinct patterns of α-synuclein accumulation in the brain, aiding our understanding of its role in disease progression. Explore our detailed findings in the full blog post: https://hubs.li/Q02tksHr0 #ParkinsonsDisease #Neuroscience #PreclinicalResearch #Biotech

Over a century since Alois Alzheimer first described Alzheimer's disease, our understanding has grown significantly, yet its actual trigger has remained elusive. Exciting new findings from an NIA study suggest a potential breakthrough. This research sheds light on a specific molecular pathway, ApoER2-Dab1, implicated in late-onset Alzheimer's disease. Malfunctioning of this pathway in human brain neurons leads to tau accumulation and early neuron death—a critical aspect of Alzheimer's pathology. Published in Acta Neuropathologica Communications, these insights offer hope for uncovering the disease's origins and identifying new therapeutic targets. Learn more: [Disruption of Molecular Pathway in Alzheimer's] (https://lnkd.in/gJV4eJpr) #AlzheimersResearch #Neuroscience #NIAHealth #EndAlz

A team led by #Ziyuan Guo from the University of Cincinnati and Cincinnati #Children's Hospital has successfully developed the world's first human mini-brain with a fully functional blood-brain barrier (BBB). This revolutionary achievement, made possible through collaboration with the Mayo Clinic and the University of California San Diego, has the potential to transform our understanding and treatment of brain disorders such as cancer, #Alzheimer's, and Parkinson's disease. The human BBB model is a game-changer in neurological research and drug discovery, offering unprecedented opportunities to study BBB functionality and develop therapeutic interventions. This breakthrough could lead to new treatments for a range of brain conditions, including stroke, cerebral vascular disorders, and neurodegenerative diseases. #LatestPakistan #ArabTimesNews #BrainResearch #Neuroscience #BloodBrainBarrier #MiniBrain #ScientificBreakthrough